TBPMF - Tetra Bio-Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4325
-0.0247 (-5.40%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.4572
Open0.4371
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4325 - 0.4559
52 Week Range0.4325 - 1.1000
Volume83,870
Avg. Volume61,622
Market Cap79.819M
Beta (3Y Monthly)2.37
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • CNW Group9 days ago

    Crescita Therapeutics Reports 2019 First Quarter Results

    Crescita Therapeutics Reports 2019 First Quarter Results

  • GlobeNewswire10 days ago

    Tetra Bio-Pharma Announces the Retirement of Bernard Lessard and the Appointment of Sabino Di Paola as Chief Financial Officer

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), today announced the retirement of Bernard Lessard as Chief Financial Officer and the appointment of Sabino Di Paola as his replacement effective May 15. "Bernard recently advised us of his wish to retire after almost two years in his role of Chief Financial Officer.

  • GlobeNewswire15 days ago

    Tetra Bio-Pharma’s Recently acquired Wholly Owned Subsidiary Panag Pharma Provides an Update on Recent Activities

    PANAG Pharma Inc. (PANAG), a wholly owned subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a bio-pharmaceutical company engaged in cannabinoid-based drug discovery and development, is pleased to provide investors with an update on the activities of PANAG including, but not limited, to its innovative and patented formulations for the treatment of uveitis  which will enter Phase 2 in late 2019. “As a result of this acquisition, we have added highly qualified experts in cannabinoid science and medicine as well as a wealth of drug discovery and early phase drug development expertise and experience.

  • GlobeNewswire22 days ago

    Tetra Bio-Pharma Closes the Acquisition of Panag Pharma

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), is pleased to announce that it completed today the previously-announced acquisition (the "Acquisition") of Panag Pharma Inc. ("Panag") pursuant to a share purchase agreement (the "Agreement") dated January 30, 2019 between the Company and the shareholders of Panag (the "Vendors"). Pursuant to the Agreement, Tetra acquired 100% of the issued and outstanding common shares of Panag held by the Vendors in consideration for, in aggregate, (i) $3,000,000 in cash and (ii) the issuance of 16,304,348 class A common shares of Tetra ("Common Shares") at a price of $0.552 per Common Share.

  • GlobeNewswire24 days ago

    Tetra Natural Health Announces The Arrival of 20 containers of Hemp Energy Drink in Canada

    Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), announces the arrival of twenty (20) containers, or more than 1.7 million cans, of its Hemp Energy Drink in Canada, the first 100% natural energy drink made from hemp in the country. Since the beginning of the year, Hemp Energy Drink (www.hempenergydrink.ca) has been available in many stores across Western Canada.

  • GlobeNewswire25 days ago

    Tetra Bio-Pharma and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development

    Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a Joint Venture Agreement under which the two companies will work together to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need. New Routes of Administration: Altus’ SmartCelle™ insoluble drug delivery platform enables intravenous, topical, intra-nasal and oral delivery. Smartcelle’s™ proven ability to enhance the solubility of cannabinoids permits increased oral absorption and enables low volume parenteral and transmucosal delivery.  Intellitab™ and Flexitab™ technologies will deliver Safer to Use™ products to patients.

  • GlobeNewswirelast month

    Tetra Bio-Pharma Shareholders Approve the Acquisition of Panag Pharma

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), is pleased to announce that, at a special meeting of shareholders held today (the "Meeting"), the shareholders of the Company voted in favor of an ordinary resolution (the "Resolution") to approve the previously announced acquisition of Panag Pharma Inc. ("Panag"), including the approval of the acceleration events, all as more particularly described in the management information circular sent to shareholders of the Company ahead of the Meeting (the "Proposed Transaction"). The Proposed Transaction was announced on January 30, 2019. Panag is a Canadian-based life sciences company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation.

  • GlobeNewswirelast month

    Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), today announced that it has entered into a collaboration agreement with Ovensa Inc. ("Ovensa") to evaluate TRIOZAN™, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells. "Glioblastoma multiforme (GBM) is a common and fatal type of brain cancer and sadly took the lives of Senator John McCain and singer Gordon Downey.

  • GlobeNewswirelast month

    Tetra Bio-Pharma Resumes its Phase 3 Clinical Trial Program

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), today announced it is ready to resume its Phase 3 clinical program in advanced cancer pain patients with the objective to assess Health- Related Quality of Life (HrQoL). The SERENITY© Study will use a vaporizer, a Health Canada approved Class 2 medical device as a delivery mechanism which is more acceptable to hospitals and palliative care centers. Tetra’s new drug formerly referred to as PPP-001 will be investigated in the SERENITY © Study under the commercial trademark of CAUMZ.

  • GlobeNewswire2 months ago

    Tetra Bio-Pharma Announces Employment Contract Renewal of CEO Guy Chamberland

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), today announced that the Company has renewed its CEO Guy Chamberland’s employment agreement. “We are extremely pleased with the progress that Guy has made since joining the company in 2016 and especially impressed with his accomplishments since being named CEO. Tetra is in the enviable position of having one of the most advanced pipeline of cannabinoid-based drug candidates in North America, working with Health Canada and the FDA, on clinical trial programs with cannabinoid-derived medicines,” stated Tetra Bio-Pharma’s Chairman of the Board, Bill Cheliak.

  • GlobeNewswire2 months ago

    Tetra Bio-Pharma to File PPP001 With the European Medicines Agency

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal medicinal product to the European Medicines Agency. The pre-marketing application of PPP001 as a herbal medicinal product specifically for the European market in no way changes Tetra’s planned schedule to restart its Phase 3 Oncology Drug Development program for advanced cancer pain that was temporarily suspended in February 2019. Tetra Bio-Pharma has gathered impressive scientific, clinical and safety data on PPP001, a dry pellet made of 3 strains of cannabis that generates a unique composition of medicinal products when administered to patients with Tetra’s class II medical devices and by smoking or vaporization.

  • GlobeNewswire3 months ago

    Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team

    Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (TBPMF), a global leader in cannabinoid-derived drug development and discovery today announced the promotion of Aurelia De Pauw to Vice-President, Clinical Programs and Medical Affairs. In her new role Dr. De Pauw will be responsible for of all clinical operations and relations with the medical community, building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company.

  • GlobeNewswire3 months ago

    Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a global leader in cannabinoid-derived drug development and discovery, is pleased to announce completion of the first double-blind, randomized and placebo-controlled Phase 2 clinical trial of cannabis oil capsules. The trial evaluated the safety and efficacy of different doses and ratios of medical cannabis oil comprised of THC and CBD, for the treatment of uncontrolled chronic pain in cancer and non-cancer patients. The Phase 2 trial was conducted by Montreal-based Santé Cannabis, Quebec's first clinical research organization specializing in cannabis and cannabinoids for medical purposes.

  • Two in Three (65%) Canadians Would Take a Drug Containing Cannabis if Prescribed by a Doctor and Covered by Insurance
    CNW Group3 months ago

    Two in Three (65%) Canadians Would Take a Drug Containing Cannabis if Prescribed by a Doctor and Covered by Insurance

    Majority of Canadians (54%) believe taking cannabis for medical reasons without consulting a doctor poses a risk. Knowledge of Canadian clinical trials investigating cannabis medicines is low. Slim majority of Canadians agree that their doctor is informed enough to treat them with cannabis.

  • GlobeNewswire3 months ago

    The Hemp Energy Drink arrives in store!

    Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), announces that Hemp Energy Drink cans are now available in 59 grocery stores and convenience stores in British Columbia, Alberta, and Saskatchewan. In British Columbia the Hemp Energy Drink is available to consumers in Vancouver, Balfour, Burnaby, Castlegar, Clearwater, Grand Forks, Hope, Houston, Kaslo, Keremeos, Ladner, Langley, Lillooet, Nanaimo, Nelson, North Vancouver, Oliver, Osoyoos, Port Alberni, Robson, Rossland, Salt Spring Island, Simon Fraser University, Slocan Park, Squamish, Summerland, Surrey, Trail, Vernon, Victoria, West Kelowna, Whistler and White Rock. In Alberta, the Hemp Energy Drink can be found in Athabasca, Banff, Boyle and Langdon, and in Saskatchewan in Kindersley and Tisdale.

  • GlobeNewswire3 months ago

    Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program

    A Phase 1 study in healthy volunteers using vaporized PPP001 was successfully completed (click here) and the Corporation filed a patent application after unexpectedly discovering the unique composition of cannabis smoke.  In July 2018, the Corporation entered into a co-development agreement with Storz & Bickel, widely recognized as the global leader in vaporizer design and manufacturing. Tetra incorporated the vaporizer into its smoke-vapor research program as it aimed to understand how inhaled cannabis relieves pain for patients.

  • GlobeNewswire3 months ago

    Tetra Bio-Pharma Announces Stock Option Grants

    Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (TBPMF), announces today that it has granted, pursuant to the Company's stock option plan (the "Plan"), 375,000 options to officers of the Company. Each option entitles its holder to purchase one common share of the Company. All of the options are subject to the terms of the Plan and the requirements of the TSX Venture Exchange.

  • GlobeNewswire3 months ago

    Tetra Bio-Pharma Pursues Its Research Priorities Accelerating Other Drug Development Plans

    Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced a change in their Drug Development Plan (DDP) priorities. This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI).  Through an expanded and focused pipeline, the Corporation intends to maintain its position as a leader in cannabis and cannabinoid drug development with a clear objective to generate value for shareholders.  In addition to its DDP in oncology and neuropathic pain programs, Tetra will pursue the development of prescription products in ophthalmic, dermatology as well as other pain segments.

  • GlobeNewswire4 months ago

    Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), today announced that it has temporarily suspended its phase 3 clinical program due to impurities found in its PPP001 investigational drug being administered to patients.  This suspension does not affect the timing of the European application nor the development of the second-generation inhalation products. Quality standards and process validations are imposed by pharmaceutical Good Manufacturing Practices (GMP).  Just like our food chain, botanical drugs have unique challenges because of the potential for microbial contamination known as mycotoxins.  Tetra’s investigational drug is composed of raw cannabis materials.

  • CNW Group4 months ago

    Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra's Dermatology Product Portfolio

    LAVAL, QC , and ORLEANS, ON , Feb. 4, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita") (CTX.TO), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, ("Tetra") (TBP.V) (TBPMF) today announced an agreement to develop an enhanced version of Tetra's dermatology portfolio using Crescita's patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene ("Beta-C"), which is known to work on Cannabidiol ("CBD") 2 receptors.

  • GlobeNewswire4 months ago

    Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio

    Crescita Therapeutics Inc. ("Crescita") (CTX.TO), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, ("Tetra") (TBP.V) (TBPMF) today announced an agreement to develop an enhanced version of Tetra’s dermatology portfolio using Crescita’s patented transdermal delivery technologies: Multiplexed Molecular Penetration Enhancer ("MMPE™") and DuraPeel™. The primary active ingredient contained in the product portfolio to be reformulated is beta-caryophyllene ("Beta-C"), which is known to work on Cannabidiol ("CBD") 2 receptors. The testing methodology and the clinical development made possible by the collaboration will help optimize the delivery of Beta-C and several other active ingredients into the skin and local tissues.

  • CNW Group4 months ago

    Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.

    ORLEANS, ON , Jan. 30, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TBP.V) (TBPMF), today announced it has entered into a definitive agreement (the "Agreement") with the shareholders (the "Vendors") of Panag Pharma Inc. ("Panag") for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the "Proposed Transaction").  Panag is a Canadian-based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation.  Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain.

  • GlobeNewswire4 months ago

    Tetra Bio-Pharma Files Patent Application to Protect PPP001

    Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.

  • GlobeNewswire4 months ago

    Tetra Natural Health Adds New Leaders to its Commercial Operations

    Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (TBPMF), is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics. Derek Theriault, National Sales Director – has 20 years’ experience within the pharmaceutical industry and has held various sales and leadership roles during this time.

  • CNW Group4 months ago

    The Lung Association - Ontario and Tetra Bio-Pharma partner to help fill the gaps in cannabis research

    TORONTO , Jan. 10, 2019 /CNW/ - With the recent legalization of recreational cannabis in Canada , a major gap has been revealed, and that is a lack of scientific research on the health effects of its use – both on the recreational and medical side. The Lung Association – Ontario and Tetra Bio-Pharma are excited to be partnering to fill that gap by funding a research program that will investigate various health impacts of cannabis use. The goal of this program will be to better support patients and healthcare providers with evidence-based information.